Extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE) infections: are carbapenem alternatives achievable in daily practice?

International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases
B PilmisJ R Zahar

Abstract

To avoid the use of carbapenems, alternatives such as cephamycin, piperacillin-tazobactam, and others are suggested for the treatment of extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE) infections. The aim of this study was to evaluate the frequency and the feasibility of antimicrobial de-escalation for ESBL-PE-related infections. A prospective observational, bi centric cohort study was conducted. All patients with ESBL-PE infections were included. De-escalation was systematically suggested if patients were clinically stable and the isolate was susceptible to possible alternatives. Seventy-nine patients were included: 36 (45.6%) were children, 27 (34.1%) were hospitalized in intensive care units, and 37 (47%) were immunocompromised. Urinary tract infections, pneumonia, and catheter-related bloodstream infections accounted for 45.6%, 19%, and 10%, respectively, of the cohort. Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae were the three most frequent causative organisms isolated. On day 5, 47 (59.2%) of the patients were still receiving carbapenems. Antimicrobial resistance (44.7%), infection relapse (26.9%), and clinical instability (19.2%) were the most important reasons for not prescr...Continue Reading

References

Jan 6, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Emilio BouzaPatricia Muñoz
Feb 6, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Lionel A MandellUNKNOWN American Thoracic Society
Jun 6, 2007·Intensive Care Medicine·Elpis GiantsouKonstantinos Manolas
Mar 29, 2008·American Journal of Infection Control·Kurt B StevensonJulie E Mangino
Sep 24, 2008·Archives of Internal Medicine·Jesús Rodríguez-BañoAlvaro Pascual
Dec 26, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Joseph S SolomkinJohn G Bartlett
Aug 27, 2011·Clinics in Chest Medicine·Michael S Niederman, Vasiliki Soulountsi
Jan 20, 2012·The Journal of Antimicrobial Chemotherapy·J RobertUNKNOWN Surveillance de la prescription des antibiotiques (SPA) Group
Mar 21, 2012·Critical Care Medicine·Sarah HeenenJean-Louis Vincent
Apr 18, 2012·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·R CantónUNKNOWN European Network on Carbapenemases
Oct 24, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Nan-Yao LeeWen-Chien Ko
Jul 11, 2013·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·T DeloryP Lesprit
Apr 18, 2015·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·E WeissUNKNOWN 'De-escalation' Study Group

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.